Latest revenue
$5.2M
as of 2026-03-31
Latest net income
$-1.5M
as of 2026-03-31
Net margin
-28.1%
as of 2026-03-31
Price · 5Y
Market data
Price feed temporarily unavailable for FOXO.
5-year trend
What this company does
Item 1. Business Overview FOXO Technologies Inc., is a healthcare services and technology company. We currently operate four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. Our mission is to build healthier communities by encompassing technology and expertise to offer a diverse and adaptable range of healthcare services and solutions to improve the quality of healthcare and lives for those we serve. Our Business Operations FOXO Technologies Inc., (“FOXO”) formerly known as Delwinds Insurance Acquisition Corp., a…
AI summary unavailable — showing raw filing excerpt
Generated from FOXO's filing dated 2026-04-15
Key risks
Item 1A. Risk Factors The following risks could materially and adversely affect our business, financial condition, cash flows, and results of operations, and the trading price of our Class A Common Stock could decline. These risk factors do not identify all risks that we face. Our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. Refer also to the other information set forth…
AI summary unavailable — showing raw filing excerpt
Generated from FOXO's filing dated 2026-04-15
Profitability
Gross margin
8.9%
72.6%Operating margin
-63.1%
67.1%Net margin
-75.9%
75.2%Return on equity
-111.5%
52.1%Return on assets
-27.9%
6.3%Leverage
Debt / equity
3.00×
56.1%Long-term debt / equity
0.26×
Debt / assets
75.0%
14.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $5.2M | +63.0% | $-1.5M | -135.5% | -28.1% |
Q4 2025 2025-12-31 | $4.4M | +57.1% | $-9.4M | -38.6% | -212.5% |
Q3 2025 2025-09-30 | $3.5M | +196.7% | $-1.9M | +3.6% | -52.9% |
Q2 2025 2025-06-30 | $5.2M | +18893.9% | $-522.0K | +75.9% | -10.0% |
Q1 2025 2025-03-31 | $3.2M | +45184.6% | $-616.5K | +59.0% | -19.4% |
Q4 2024 2024-12-31 | $2.8M | — | $-6.8M | — | -240.8% |
Q3 2024 2024-09-30 | $1.2M | +11860.0% | $-1.9M | +46.8% | -162.7% |
Q2 2024 2024-06-30 | $27.5K | +129.0% | $-2.2M | +80.8% | -7872.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on FOXO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for FOXO in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns FOXO
Institutional value
$0
Total shares held
181
Distinct holders
1
-11 vs prior
As of
2025-12-31
Prior: 2025-06-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Garton & Associates Financial Advisors LLC | 181 | $0 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once FOXO's latest filing finishes processing.